Suchen
Silence Therapeutics PLC
SLNZur Watchlist hinzufügen
10.390USD
-0.110-1.05%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
490.76MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Silence Therapeutics PLC Unternehmen
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Silence Therapeutics PLC Informationen
BörsenkürzelSLN
Name des UnternehmensSilence Therapeutics PLC
IPO-datumJan 05, 2010
CEOTooman (Craig A)
Anzahl der mitarbeiter116
WertpapierartDepository Receipt
GeschäftsjahresendeJan 05
Addresse72 Hammersmith Road
StadtLONDON
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited Kingdom
PostleitzahlW14 8TH
Telefon442034576900
Websitehttps://www.silence-therapeutics.com/
BörsenkürzelSLN
IPO-datumJan 05, 2010
CEOTooman (Craig A)
Führungskräfte von Silence Therapeutics PLC
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Timothy (Tim) McInerney
Mr. Timothy (Tim) McInerney
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. David Jakob (Dave) Lemus, CPA
Mr. David Jakob (Dave) Lemus, CPA
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Iain Gladstone Ross
Mr. Iain Gladstone Ross
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Dr. Steven J. Romano, M.D.
Dr. Steven J. Romano, M.D.
Executive Vice President, Chief of Research and Development Officer
Executive Vice President, Chief of Research and Development Officer
--
--
Mr. Craig A. Tooman
Mr. Craig A. Tooman
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
--
--
Ms. Gem Hopkins
Ms. Gem Hopkins
Head of IR and Corporate Communications
Head of IR and Corporate Communications
--
--
Ms. Rhonda Heliums
Ms. Rhonda Heliums
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von Silence Therapeutics PLC?
Die fünf größten Anteilseigner von Silence Therapeutics PLC sind: Mr. David Jakob (Dave) Lemus, CPA
Wie viele Institutionen halten Anteile an Silence Therapeutics PLC (SLN)?
Mit Stand vom 2026Q1 halten 147 Institutionen Anteile an Silence Therapeutics PLC, mit einem Gesamtmarktwert von etwa 19.17M, was 40.59% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -12508865.00 gestiegen.